<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559256</url>
  </required_header>
  <id_info>
    <org_study_id>HDZ-KA_018_MG</org_study_id>
    <nct_id>NCT04559256</nct_id>
  </id_info>
  <brief_title>Tricuspid Cardiopulmonary Exercise Study</brief_title>
  <acronym>TRCPET</acronym>
  <official_title>Transcatheter Tricuspid Valve Interventions and Right Ventricular Function: Evaluation With Cardiopulmonary Exercise Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart and Diabetes Center North-Rhine Westfalia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heart and Diabetes Center North-Rhine Westfalia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tricuspid regurgitation (TR), which in close to 90% of cases is functional as a consequence&#xD;
      of left-sided heart failure, left heart valve abnormalities or pulmonary (vascular) disease,&#xD;
      is associated with adverse patient outcomes . Due to the increased risk of surgical tricuspid&#xD;
      valve repair or replacement compared to surgery in left-sided valve disease TR is often&#xD;
      undertreated. Treatment options for the tricuspid valve have so far been limited.&#xD;
      Conservative therapy over longer. periods usually results in refractoriness to diuretic&#xD;
      treatment. Surgical therapy is associated with a high rate of in-hospital mortality (8.8%),&#xD;
      the cause of which is not yet fully understood but may partly be explained by the hemodynamic&#xD;
      challenge that cardiopulmonary bypass imposes on the often already-dysfunctional right&#xD;
      ventricle. Recently, transcatheter strategies have been developed and have shown promising&#xD;
      results. Despite the promising data it has so far not be determined objectively whether&#xD;
      interventional treatment of isolated tricuspid regurgitation improves exercise capacity and&#xD;
      what role right ventricular function plays in this setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on peak oxygen uptake</measure>
    <time_frame>3 month</time_frame>
    <description>Changes on maximal oxygen uptake (peak VO2) assessed by cardiopulmonary exercise testing (CPET, spiroergometry) after transcatheter tricuspid intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on duration of submaximal exercise tolerance</measure>
    <time_frame>3 month</time_frame>
    <description>Changes on the duration of submaximal exercise tolerance assessed by exercise time during high-intensity constant-work rate endurance tests (CWRET) after transcatheter tricuspid intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on the minute ventilation/carbon dioxide production slope in the cardiopulmonary exercise testing</measure>
    <time_frame>3 month</time_frame>
    <description>Changes on the minute ventilation/carbon dioxide production slope in the cardiopulmonary exercise testing after transcatheter tricuspid intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of oscillatory respiration pattern</measure>
    <time_frame>3 month</time_frame>
    <description>Detection of oscillatory respiration pattern before and 3 months after transcatheter tricuspid intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Testing with 6 min walking test</measure>
    <time_frame>3 month</time_frame>
    <description>Changes on walked distance after transcatheter tricuspid intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of moderate to severe or severe tricuspid regurgitation</measure>
    <time_frame>3 month</time_frame>
    <description>Detection of the prevalence of moderate to severe or severe tricuspid regurgitation after transcatheter tricuspid intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization rate for heart failure</measure>
    <time_frame>3 month</time_frame>
    <description>Detection of rehospitalization rate after transcatheter tricuspid intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on NYHA class</measure>
    <time_frame>3 month</time_frame>
    <description>Changes on NYHA class after transcatheter tricuspid intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on quality of life</measure>
    <time_frame>3 month</time_frame>
    <description>Changes on the Minnesota Living with Heart Failure Questionnaire score after transcatheter tricuspid intervention (0-105 points on a global scale, with 0 points representing a very good quality of life and 105 points representing a very reduced quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on the left an right ventricle</measure>
    <time_frame>3 month</time_frame>
    <description>Echocardiographic assessment of left and right ventricular remodeling after transcatheter tricuspid intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of transcatheter tricuspid intervention on serum N terminal-proBNP level</measure>
    <time_frame>3 month</time_frame>
    <description>Changes on serum N terminal-proBNP-level after transcatheter tricuspid intervention</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>Tricuspid Cardiopulmonary Exercise testing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient receiving cardiopulmonary exercise testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiopulmonary Exercise Testing</intervention_name>
    <description>Patients will receive a cardiopulmonary exercise testing before and 3-month after tricuspid intervention</description>
    <arm_group_label>Tricuspid Cardiopulmonary Exercise testing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic tricuspid regurgitation 2+ to 4+ on a scale of 4+ (moderate to severe) with&#xD;
             annular diameter ≥ 40 mm with valve systolic pulmonary pressure (sPAP) ≤ 60 mmHg&#xD;
&#xD;
          -  New York Heart Association (NYHA) Class II-IV&#xD;
&#xD;
          -  Symptomatic despite Guideline Directed Medical Therapy (GDMT); at minimum patient on&#xD;
             diuretic regimen&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥ 30%&#xD;
&#xD;
          -  Symptomatic despite Guideline Directed Medical Therapy (GDMT); at minimum patient on&#xD;
             diuretic regimen&#xD;
&#xD;
          -  The local site Heart Team concur that surgery will not be offered as a treatment&#xD;
             option&#xD;
&#xD;
          -  Written informed consent in accordance with Good Clinical Practice (GCP) and local&#xD;
             legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to perform cardiopulmonary exercise test&#xD;
&#xD;
          -  Aortic, mitral and/or pulmonic valve stenosis and/or regurgitation ≥ moderate&#xD;
&#xD;
          -  Previous tricuspid valve repair or replacement&#xD;
&#xD;
          -  Severe precapillary pulmonary hypertension (PVR&gt;6 WE)&#xD;
&#xD;
          -  Cerebrovascular accident (CVA) within the past 6 months&#xD;
&#xD;
          -  Presence of trans-tricuspid pacemaker or defibrillator leads which cause impingement&#xD;
             of the tricuspid valve leaflet as evaluated by echocardiography&#xD;
&#xD;
          -  Subject is on chronic dialysis and/or anemia (Hb &lt; 9 g/L)&#xD;
&#xD;
          -  Myocardial infarction or known unstable angina within 30 days prior to the index&#xD;
             procedure&#xD;
&#xD;
          -  Any percutaneous coronary intervention or transcatheter valvular intervention within&#xD;
             30 days prior to the index procedure or planned 3 months post the index procedure&#xD;
&#xD;
          -  Previous tricuspid valve repair or replacement&#xD;
&#xD;
          -  Life expectancy of less than 12 months&#xD;
&#xD;
          -  Patients with cardiac cachexia&#xD;
&#xD;
          -  Echocardiographic evaluation not available or not suitable for analysis at baseline&#xD;
&#xD;
          -  Unsuitable anatomy for transcatheter tricuspid intervention&#xD;
&#xD;
          -  Key information from patients (e.g. NYHA, TR grade) not available&#xD;
&#xD;
          -  Known allergy or intolerance against the studied device&#xD;
&#xD;
          -  Persons held in an institution by legal or official order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammed Gerçek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart and Diabetes Center North-Rhine Westfalia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammed Gerçek, MD</last_name>
    <phone>05731970</phone>
    <email>mugercek@hdz-nrw.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum, NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>NRW</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammed Gercek, Dr. med</last_name>
      <phone>00495371971258</phone>
      <email>mugercek@hdz-nrw.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heart and Diabetes Center North-Rhine Westfalia</investigator_affiliation>
    <investigator_full_name>Muhammed Gerçek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Tricuspid Regurgitation</keyword>
  <keyword>Cardiopulmonary Exercise Testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

